-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Accurate assessment of prognosis is critical for stroke trials and clinical care; however, there are different ways to measure recovery after stroke
Accurate assessment of prognosis is critical for stroke trials and clinical care; however, there are different ways to measure recovery after stroke
The ordinal mRS grades were not equally and to some extent arbitrarily spaced—making it potentially challenging to interpret differences in disability between each level
Upper extremity (UE) deficits are the most common source of disability and a factor affecting overall quality of life and subjective well-being after stroke
The study specifically aimed to (1) determine whether mRS levels can discriminate between different detailed phenotypes of injury and function; (2) correlate mRS results with meaningful changes in injury and function in a cohort of UE patients recovering from the acute to subacute phase of stroke to compare
Methods: Patients with upper extremity weakness after ischemic stroke underwent a series of functional impairment and functional measures at 1 week and 90 days after stroke
Methods: Patients with upper extremity weakness after ischemic stroke underwent a series of functional impairment and functional measures at 1 week and 90 days after stroke
result:
result:- In this cohort of 73 stroke patients, impairment and functional outcomes correlated with 90-day mRS scores, but exhibited substantial variability within individual mRS levels: within mRS grade 2, upper extremity impairment ranged from near-hemiplegic (upper extremity fugl -meyer 8) to no injury (upper extremity fugl-meyer 66)
in conclusion:After the stroke trial confirmed the exact value of stroke, mRS was roughly associated with domain-specific outcomes, but it did not accurately distinguish differences between lesions and function, nor did it adequately capture meaningful clinical changes across lesions, ADL status, and mobility
After the stroke trial confirmed the exact value of stroke, mRS was roughly associated with domain-specific outcomes, but it did not accurately distinguish differences between lesions and function, nor did it adequately capture meaningful clinical changes across lesions, ADL status, and mobility
Source: Erler KS, Wu R, DiCarlo JA, et al.
Association of Modified Rankin Scale With Recovery Phenotypes in Patients With Upper Extremity Weakness After Stroke [published online ahead of print, 2022 Mar 11].
Neurology.
2022;10.
1212/WNL .
0000000000200154.
doi:10.
1212/WNL.
0000000000200154
leave a message here
